共 50 条
- [41] The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-AnalysisJOURNAL OF CANCER, 2020, 11 (11): : 3106 - 3113Zhao, ZheLi, LuWang, ZhijieDuan, JianchunBai, HuaWang, Jie
- [42] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung CancerCLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622Skoulidis, FerdinandosPapadimitrakopoulou, Vassiliki A.
- [43] Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practicePLOS ONE, 2019, 14 (01):Oh, Dong KyuJi, Won JunKim, Woo SungChoi, Chang-MinYoon, Shin-KyoRho, Jin KyungLee, Jae Cheol
- [44] Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib ProgressJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S882 - S882Huang, R.Xu, C.Wang, W.Li, J.He, C.Zhu, Y.Zhuang, W.Huang, Z.Chen, Y.Chen, G.Fang, M.Lv, T.Song, Y.
- [45] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung CancerClinical Drug Investigation, 2022, 42 : 459 - 464Sha LiuTao PanMing-Kun WangJie WangShuang ZhangPing Zhou
- [46] Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung CancerCLINICAL DRUG INVESTIGATION, 2022, 42 (05) : 459 - 464Liu, ShaPan, TaoWang, Ming-KunWang, JieZhang, ShuangZhou, Ping
- [47] Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer GroupBMC Cancer, 21Mariano ProvencioJosefa TerrasaPilar GarridoRosario García CampeloFrancisco AparisiPilar DizDavid AguiarCarlos García-GironJulia HidalgoCarlos AguadoJorge García GonzálezEmilio EstebanLorenzo Gómez-AldavaríTeresa MoranOscar JuanLuís Enrique CharaJuan L. MartiRafael López CastroAna Laura OrtegaElia Martínez MorenoJuan CovesAna M. Sánchez PeñaJoaquim Bosch-BarreraAmparo Sánchez GastaldoNatalia Fernández NúñezEdel del BarcoManuel CoboDolores IslaMargarita MajemFátima NavarroVirginia Calvo
- [48] Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)ANNALS OF ONCOLOGY, 2019, 30 : 624 - 624Metro, G.Provencio, M.Kim, D-W.Cho, B. C.Park, K.Pan, Y.Shi, Y.Migliorino, R.Tiseo, M.Yu, J.Zhou, Q.Santo, A.Ardizzoni, A.Hu, Y.Wu, Y-L.Kim, S-W.Miranda, M.Fernandes, A.de Marinis, F.
- [49] ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in SpainJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S93 - S94Vicente Baz, D.Paredes Lario, A.Moran Bueno, M. T.Massuti Sureda, B.Reguard, N.Alvarez, R.Insa Molla, A.Juan, O.Marquez, G.Provencio Pulla, M.
- [50] Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer GroupBMC CANCER, 2021, 21 (01)Provencio, MarianoTerrasa, JosefaGarrido, PilarGarcia Campelo, RosarioAparisi, FranciscoDiz, PilarAguiar, DavidGarcia-Giron, CarlosHidalgo, JuliaAguado, CarlosGarcia Gonzalez, JorgeEsteban, EmilioGomez-Aldavari, LorenzoMoran, TeresaJuan, OscarEnrique Chara, LuisMarti, Juan L.Lopez Castro, RafaelLaura Ortega, AnaMartinez Moreno, EliaCoves, JuanSanchez Pena, Ana M.Bosch-Barrera, JoaquimSanchez Gastaldo, AmparoFernandez Nunez, Nataliadel Barco, EdelCobo, ManuelIsla, DoloresMajem, MargaritaNavarro, FatimaCalvo, Virginia